Araştırma Makalesi
BibTex RIS Kaynak Göster

Treatment Combinations and Prognosis in Multiple Resistant Acinetobacter baumannii and Carbapenem Resistant Klebsiella pneumonıae/oxytoca Isolates

Yıl 2021, Cilt: 6 Sayı: 3, 121 - 128, 30.10.2021

Öz

Multi-drug-resistant (MDR) gram-negative bacterial infections are one of the most important causes of prolonged hospitalization and mortality in patients followed up in the İntensive Care Unit (ICU). In our study, we retrospectively scanned the blood and tracheal aspirate cultures (TAC) of patients hospitalized in the ICUs of our hospital. We investigated the effects of demographic characteristics, comorbid conditions, treatment combinations and time of treatment on survival of 83 patients with MDR Acinetobacter baumannii and Klepsiella pneumoniae/oxytoca strains in culture samples from 450 cases. Of the patients, 48 (57.83%) were male, and 35 (42.17%) were female. Of all cases, the average age (years) was average±SD (Min-Max), 76.24±13 (23-96). Length of stay in intensive care, the average (day) was 25.61±19.1 (1-107). Cerebrovascular Dısease (CVD) was the most common (20%) comorbidity. A. baumannii was grown in 31 (37.3%) patients, K. pneumoniae was grown in 50 (60.3%) patients, and K. oxytoca was grown in 2 (2.4%) patients. Age (p=0.793), sex (p=0.429), length of hospital stay (p=0.097), number of comorbidities (p=0.553), treatment combinations (p=0.727), pathogen type (p=0.622), growth in blood culture and/or TAC (p=0.369), there was no statistically significant difference indicating that factors such as increased mortality. It was observed that intubation (p=0.004) and duration of treatment of 7 days or less (p=0.001) significantly reduced survival. In the treatment of MDR Acınetobacter and Klebsıella, ıntubatıon and duratıon of treatment affected survıval, but than combınatıon.

Proje Numarası

YOK

Kaynakça

  • References 1. Souli M, Gallani I, Giamarellou H. Emergence of extensively drug resistant and pan-drug resistant Gram negative bacilli in Europe. Eurosurveillance 2008, 13 (47):20.
  • 2. Akçam FZ. Karbapenem Dirençli Enterobakteriler:Nasıl Başa Çıkılır? FLORA 2019;24(2):75-86.
  • 3. Temel A, Eraç B. Küresel bir tehdit: Acinetobacter baumannii, antimikrobiyal dirençte güncel durum ve alternatif tedavi yaklaşımları. Turk Hij Den Biyol Derg, 2020; 77(3): 367-378
  • 4. Sheu CC, Chang YT, Lin SY, et al. Infections caused by carbapenem-resistant Enterobacteriaceae: An update on therapeutic options. Front Microbiol. 2019;10:80.
  • 5. Bal Ç. Beta-laktamazlar: güncel durum. FLORA 2003;8:111-23.
  • 6. Usluer G. Çoklu dirençli patojenler: epidemiyoloji ve kontrol. FLORA 2002;7:135-41.
  • 7. Logan LK, Weinstein RA. The epidemiology of carbapenem- resistant enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis 2017;215:28-36.
  • 8. Eser F, Yılmaz GR, Güner R, Koçak Tufan Z, Güven T, Açıkgöz ZC ve ark. Karbapenem dirençli Enterobacteriacae infeksiyonları: risk faktörleri. Akd Tıp D 2018;2:144-51.
  • 9. Wroblewska MM, Rudnicka J, Marchel H, Luczak M. Multidrug-resistant bacteria isolated fram patients hospitalised in intensive care units. Int J Antimicrob Agents 2006; 27: 285-9.
  • 10. Akan Ö, Uysal S. Çoklu Dirençli Acınetobacter baumannıı ve Karbapenem Dirençli Klebsıella pneumonıae İzolatlarında Tigesiklinin İn Vitro Etkinlik Durumu. MİKROBİYOL BÜL 2008; 42: 209-215.
  • 11. Dizbay M, Tunccan OG, Karasahin O, Aktas F. Emergence of carbapenem resistant Klebsiella spp. infections in a Turkish university hospital: Epidemiology and risk factors J Infect Dev Ctries 2014; 8 (1):44-9.
  • 12. Tijet N, Sheth PM, Lastovetska O, Chung C, Patel SN, Melano RG. Molecular characterization of Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae in Ontario, Canada, 2008-2011. PloS One 2014;9(12):e116421.
  • 13. Clinical and Laboratuary Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing: 20th informational supplement document M100-S20. Wayne PA: Clinical and Laboratory Standards Institute CLSI, (2010).
  • 14. Paul M, Carmeli Y, Durante-Mangoni E. Combination therapy for carbapenem resistant Gram-negative bacteria. J Antimicrob Chemother 2014;69(9):2305-9.
  • 15. Lee GC, Burgess DS. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann Clin Microbiol Antimicrob 2012; 13:11:32.
  • 16. Bacakoğlu F, Korkmaz Ekren P, Taşbakan MS, Başarık B, Pullukçu H, Aydemir Ş, Gürgün A, Kaçmaz Başoğlu Ö. Solunumsal Yoğun Bakım Ünitesinde Çoklu Antibiyotik Dirençli Acınetobacter Baumannıı Enfeksiyonu. Mikrobiyol Bul 2009; 43: 575-585.
  • 17. Doi Y, Husain S, Potoski BA, McCurry KR, Paterson DL. Extensively drug-resistant Acinetobacter baumannii. Emerg Infect Dis 2009; 15(6): 980-2.
  • 18. Joly-Guillou ML. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect 2005; 11(11):868-73.
  • 19. Towner KJ. Acinetobacter: an old friend, but a new enemy. J Hosp Infect 2009; 73(4): 355-63.
  • 20. Kuzucu Ç, Yetkin F, Görgeç S, Ersoy Y. Genişlemiş Spektrumlu Beta-Laktamaz Üreten Escherichia coli ve Klebsiella spp. Suşlarının Ertapenem ve Diğer Karbapenemlere Karşı Duyarlılıklarının Araştırılması. Mikrobiyol Bul 2011; 45(1): 28-35.
  • 21. Park Jin Ju, et al. Colistin monotherapy versus colistin-based combination therapy for treatment of bacteremia in burn patients due to carbapenem-resistant gram negative bacteria. https://doi.org/10.1016/j.burns.2020.06.014
  • 22. M. Paul, G.L. Daikos, E. Durante-Mangoni, D. Yahav, Y. Carmeli, Y.D. Benattar, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis, 18 (2018), pp. 391-400
  • 23. Gölboyu B, Dülgeroğlu O, Ekinci M, Baysal p, Kenan Murat3 Yoğun bakım ünitesinde çoklu ilaç dirençli Acinetobacter Baumanni enfeksiyonu gelişiminde rol oynayan predispozan faktörler. Tepecik Eğit. ve Araşt. Hast. Dergisi 2015; 25(3):157-164.
Yıl 2021, Cilt: 6 Sayı: 3, 121 - 128, 30.10.2021

Öz

Destekleyen Kurum

YOK

Proje Numarası

YOK

Kaynakça

  • References 1. Souli M, Gallani I, Giamarellou H. Emergence of extensively drug resistant and pan-drug resistant Gram negative bacilli in Europe. Eurosurveillance 2008, 13 (47):20.
  • 2. Akçam FZ. Karbapenem Dirençli Enterobakteriler:Nasıl Başa Çıkılır? FLORA 2019;24(2):75-86.
  • 3. Temel A, Eraç B. Küresel bir tehdit: Acinetobacter baumannii, antimikrobiyal dirençte güncel durum ve alternatif tedavi yaklaşımları. Turk Hij Den Biyol Derg, 2020; 77(3): 367-378
  • 4. Sheu CC, Chang YT, Lin SY, et al. Infections caused by carbapenem-resistant Enterobacteriaceae: An update on therapeutic options. Front Microbiol. 2019;10:80.
  • 5. Bal Ç. Beta-laktamazlar: güncel durum. FLORA 2003;8:111-23.
  • 6. Usluer G. Çoklu dirençli patojenler: epidemiyoloji ve kontrol. FLORA 2002;7:135-41.
  • 7. Logan LK, Weinstein RA. The epidemiology of carbapenem- resistant enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis 2017;215:28-36.
  • 8. Eser F, Yılmaz GR, Güner R, Koçak Tufan Z, Güven T, Açıkgöz ZC ve ark. Karbapenem dirençli Enterobacteriacae infeksiyonları: risk faktörleri. Akd Tıp D 2018;2:144-51.
  • 9. Wroblewska MM, Rudnicka J, Marchel H, Luczak M. Multidrug-resistant bacteria isolated fram patients hospitalised in intensive care units. Int J Antimicrob Agents 2006; 27: 285-9.
  • 10. Akan Ö, Uysal S. Çoklu Dirençli Acınetobacter baumannıı ve Karbapenem Dirençli Klebsıella pneumonıae İzolatlarında Tigesiklinin İn Vitro Etkinlik Durumu. MİKROBİYOL BÜL 2008; 42: 209-215.
  • 11. Dizbay M, Tunccan OG, Karasahin O, Aktas F. Emergence of carbapenem resistant Klebsiella spp. infections in a Turkish university hospital: Epidemiology and risk factors J Infect Dev Ctries 2014; 8 (1):44-9.
  • 12. Tijet N, Sheth PM, Lastovetska O, Chung C, Patel SN, Melano RG. Molecular characterization of Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae in Ontario, Canada, 2008-2011. PloS One 2014;9(12):e116421.
  • 13. Clinical and Laboratuary Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing: 20th informational supplement document M100-S20. Wayne PA: Clinical and Laboratory Standards Institute CLSI, (2010).
  • 14. Paul M, Carmeli Y, Durante-Mangoni E. Combination therapy for carbapenem resistant Gram-negative bacteria. J Antimicrob Chemother 2014;69(9):2305-9.
  • 15. Lee GC, Burgess DS. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann Clin Microbiol Antimicrob 2012; 13:11:32.
  • 16. Bacakoğlu F, Korkmaz Ekren P, Taşbakan MS, Başarık B, Pullukçu H, Aydemir Ş, Gürgün A, Kaçmaz Başoğlu Ö. Solunumsal Yoğun Bakım Ünitesinde Çoklu Antibiyotik Dirençli Acınetobacter Baumannıı Enfeksiyonu. Mikrobiyol Bul 2009; 43: 575-585.
  • 17. Doi Y, Husain S, Potoski BA, McCurry KR, Paterson DL. Extensively drug-resistant Acinetobacter baumannii. Emerg Infect Dis 2009; 15(6): 980-2.
  • 18. Joly-Guillou ML. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect 2005; 11(11):868-73.
  • 19. Towner KJ. Acinetobacter: an old friend, but a new enemy. J Hosp Infect 2009; 73(4): 355-63.
  • 20. Kuzucu Ç, Yetkin F, Görgeç S, Ersoy Y. Genişlemiş Spektrumlu Beta-Laktamaz Üreten Escherichia coli ve Klebsiella spp. Suşlarının Ertapenem ve Diğer Karbapenemlere Karşı Duyarlılıklarının Araştırılması. Mikrobiyol Bul 2011; 45(1): 28-35.
  • 21. Park Jin Ju, et al. Colistin monotherapy versus colistin-based combination therapy for treatment of bacteremia in burn patients due to carbapenem-resistant gram negative bacteria. https://doi.org/10.1016/j.burns.2020.06.014
  • 22. M. Paul, G.L. Daikos, E. Durante-Mangoni, D. Yahav, Y. Carmeli, Y.D. Benattar, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis, 18 (2018), pp. 391-400
  • 23. Gölboyu B, Dülgeroğlu O, Ekinci M, Baysal p, Kenan Murat3 Yoğun bakım ünitesinde çoklu ilaç dirençli Acinetobacter Baumanni enfeksiyonu gelişiminde rol oynayan predispozan faktörler. Tepecik Eğit. ve Araşt. Hast. Dergisi 2015; 25(3):157-164.
Toplam 23 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Klinik Tıp Bilimleri
Bölüm Araştırma Makaleleri
Yazarlar

Ahmet Doğan

Yakup Gezer

Proje Numarası YOK
Yayımlanma Tarihi 30 Ekim 2021
Yayımlandığı Sayı Yıl 2021 Cilt: 6 Sayı: 3

Kaynak Göster

APA Doğan, A., & Gezer, Y. (2021). Treatment Combinations and Prognosis in Multiple Resistant Acinetobacter baumannii and Carbapenem Resistant Klebsiella pneumonıae/oxytoca Isolates. Journal of Immunology and Clinical Microbiology, 6(3), 121-128.
AMA Doğan A, Gezer Y. Treatment Combinations and Prognosis in Multiple Resistant Acinetobacter baumannii and Carbapenem Resistant Klebsiella pneumonıae/oxytoca Isolates. J Immunol Clin Microbiol. Ekim 2021;6(3):121-128.
Chicago Doğan, Ahmet, ve Yakup Gezer. “Treatment Combinations and Prognosis in Multiple Resistant Acinetobacter Baumannii and Carbapenem Resistant Klebsiella pneumonıae/Oxytoca Isolates”. Journal of Immunology and Clinical Microbiology 6, sy. 3 (Ekim 2021): 121-28.
EndNote Doğan A, Gezer Y (01 Ekim 2021) Treatment Combinations and Prognosis in Multiple Resistant Acinetobacter baumannii and Carbapenem Resistant Klebsiella pneumonıae/oxytoca Isolates. Journal of Immunology and Clinical Microbiology 6 3 121–128.
IEEE A. Doğan ve Y. Gezer, “Treatment Combinations and Prognosis in Multiple Resistant Acinetobacter baumannii and Carbapenem Resistant Klebsiella pneumonıae/oxytoca Isolates”, J Immunol Clin Microbiol, c. 6, sy. 3, ss. 121–128, 2021.
ISNAD Doğan, Ahmet - Gezer, Yakup. “Treatment Combinations and Prognosis in Multiple Resistant Acinetobacter Baumannii and Carbapenem Resistant Klebsiella pneumonıae/Oxytoca Isolates”. Journal of Immunology and Clinical Microbiology 6/3 (Ekim 2021), 121-128.
JAMA Doğan A, Gezer Y. Treatment Combinations and Prognosis in Multiple Resistant Acinetobacter baumannii and Carbapenem Resistant Klebsiella pneumonıae/oxytoca Isolates. J Immunol Clin Microbiol. 2021;6:121–128.
MLA Doğan, Ahmet ve Yakup Gezer. “Treatment Combinations and Prognosis in Multiple Resistant Acinetobacter Baumannii and Carbapenem Resistant Klebsiella pneumonıae/Oxytoca Isolates”. Journal of Immunology and Clinical Microbiology, c. 6, sy. 3, 2021, ss. 121-8.
Vancouver Doğan A, Gezer Y. Treatment Combinations and Prognosis in Multiple Resistant Acinetobacter baumannii and Carbapenem Resistant Klebsiella pneumonıae/oxytoca Isolates. J Immunol Clin Microbiol. 2021;6(3):121-8.

88x31.png 

Creative Commons Attribution Non-Commercial License: The articles in the Journal of Immunology and Clinical Microbiology are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

JICM bir QMEL® Tıp & Yayınevi ürünüdür.